Anson Funds Management LP Sells 200,000 Shares of Taysha Gene Therapies, Inc. $TSHA

Anson Funds Management LP decreased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 24.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 603,500 shares of the company’s stock after selling 200,000 shares during the period. Anson Funds Management LP’s holdings in Taysha Gene Therapies were worth $1,973,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $157,000. Two Sigma Investments LP lifted its position in Taysha Gene Therapies by 102.3% during the third quarter. Two Sigma Investments LP now owns 66,105 shares of the company’s stock valued at $216,000 after buying an additional 33,423 shares during the period. Squarepoint Ops LLC grew its position in shares of Taysha Gene Therapies by 97.9% in the 3rd quarter. Squarepoint Ops LLC now owns 198,352 shares of the company’s stock worth $649,000 after buying an additional 98,126 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Taysha Gene Therapies during the 3rd quarter valued at about $40,000. Finally, UBS Group AG increased its stake in shares of Taysha Gene Therapies by 144.7% during the third quarter. UBS Group AG now owns 639,356 shares of the company’s stock valued at $2,091,000 after purchasing an additional 378,117 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 2.6%

Taysha Gene Therapies stock opened at $4.49 on Friday. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a market cap of $1.23 billion, a P/E ratio of -13.61 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The business has a 50-day simple moving average of $4.70 and a two-hundred day simple moving average of $4.50.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, CFO Kamran Alam sold 23,849 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the sale, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the transaction, the chief executive officer owned 2,908,257 shares in the company, valued at $13,407,064.77. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TSHA shares. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. Wells Fargo & Company increased their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Finally, Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.91.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.